Clinical Trial Detail

NCT ID NCT04068831
Title Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

renal cell carcinoma

Therapies

Avelumab + Talazoparib

Age Groups: senior adult

Additional content available in CKB BOOST